BrainStorm Reschedules Q1 2025 Financial Results Release
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a pioneer in adult stem cell therapeutics for neurodegenerative diseases, recently announced an important update regarding its financial results. The company has moved the release date for its financial performance for the first quarter, which ended on March 31, 2025, to after market close today. Alongside this change, BrainStorm has set a new date for its investor conference call, which will occur shortly on a weekday morning to facilitate discussion.
Investor Call Scheduled for May 19, 2025
The investor call is scheduled for Monday, May 19, 2025, at 8:30 a.m. Eastern Time. During this call, BrainStorm’s President and CEO, Chaim Lebovits, will provide a comprehensive corporate update followed by a question-and-answer segment. Attendees can anticipate insights from key personnel including Haro Hartounian, Ph.D., Chief Operating Officer, Bob Dagher, M.D., Chief Medical Officer, and Alla Patlis, CPA, MBA, Interim Chief Financial Officer.
How to Participate in the Conference Call
Participants interested in joining the investor call can easily access it through two main numbers. U.S.-based investors can call the toll-free number at 888-506-0062, while international participants can reach out by dialing 973-528-0011. To ensure a streamlined process, all participants will need to enter the access code 621608 when prompted.
Replay Information for Conference Call
For those unable to join the live call, a replay will be available. Interested parties can access the replay using toll-free number 877-481-4010 for U.S. calls or 919-882-2331 for international inquiries, accompanied by the reply passcode 52457. The replay service will be active for a limited duration of 14 days to ensure ample opportunity for review.
About BrainStorm Cell Therapeutics Inc.
Founded with a mission to harness the potential of adult stem cells, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is dedicated to developing innovative therapies for debilitating neurodegenerative conditions. Their flagship platform, NurOwn®, utilizes autologous mesenchymal stem cells to create neurotrophic factor-secreting cells designed to target neuroinflammation and support neuroprotection.
Currently, the NurOwn® therapy is under investigation primarily for amyotrophic lateral sclerosis (ALS), having gained Orphan Drug designation from the FDA as well as the European Medicines Agency. The recent completion of a Phase 3 trial, followed by future endeavors under a Special Protocol Assessment with the FDA, paves the way for significant advancements in ALS treatment.
BrainStorm continues its critical research efforts, focusing on ALS and exploring applications of its innovative technologies in progressive multiple sclerosis, supported by a grant from the National MS Society. Additionally, BrainStorm is advancing an allogeneic exosome-based platform aimed at delivering therapeutic proteins and nucleic acids, strengthening its intellectual property portfolio in regenerative medicine.
Frequently Asked Questions
What is the purpose of the rescheduled financial results release?
The release aims to provide shareholders with the latest financial performance metrics and company updates after the market closes, allowing for informed discussions during the investor call.
Who will join Chaim Lebovits on the investor call?
Chaim will be joined by Haro Hartounian, M.D., Bob Dagher, M.D., and Alla Patlis to address questions from investors regarding company developments and future plans.
How can I access the conference call?
Investors can join the call by dialing the numbers provided with the participant access code. It offers an opportunity to engage with company leadership directly.
Is there a replay available for the conference call?
Yes, a replay of the conference call will be available for 14 days, allowing those who missed the live session to stay updated.
Where can I find more information about BrainStorm’s therapies?
For detailed information on BrainStorm's innovative therapies and research updates, you can visit their official website.
